Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia

Byrnes, Catherine A; Liss, CL; Tenover, J. Lisa; Lippert, Marguerite C.; Jy, Gillenwater

doi:10.1038/sj.pcan.4500202

Cited by 6 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finasteride is a 5α-reductase inhibitor, which decreased PSA levels by 50% in elderly men (mean age: 64 ± 9 years) treated for benign prostatic hyperplasia for 12 months [31]. Finasteride use was associated with less but higher-grade prostate cancer in the Prostate Cancer Prevention Trial, which led to several speculations regarding bias introduced by treatment induced PSA reduction [32].…”

Section: Discussionmentioning

confidence: 99%

Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results

Wenisch

Mayr

Spiel

et al. 2013

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: Prostate-specific antigen (PSA) is used as an outcome measure for relapsed disease in prostate cancer. Nonetheless, there are considerable concerns about its indiscriminate use as a surrogate endpoint for cell growth or survival. We hypothesized that treatment with a luteinizing hormone releasing hormone (LHRH) analog would decrease PSA levels even in the absence of malignant disease. Methods: We determined testosterone and PSA levels in 30 healthy volunteers after a single intramuscular injection of a LHRH depot formulation. Testosterone and PSA levels were quantified by radioimmunoassay and electrochemi-luminescence immunoassay, respectively. Results: After an initial flare-up during the first 3 days testosterone decreased reaching castration levels in 18 of the 30 young men (60%). After the nadir on day 28, testosterone levels increased to normal again. Changes in PSA paralleled those of testosterone. Castration reduced PSA levels by 29% (95% CI 19%-39%) compared to baseline (p < 0.0001). Conclusions: LHRH superagonists decrease PSA levels by testosterone deprivation. Conferring these findings to tumor patients, decreases in PSA after treatment with LHRH analogs might not only reflect disease regression but also a direct testosterone mediated effect on PSA. Thus, PSA levels should be cautiously interpreted when patients receive hormonal therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results

Wenisch

Mayr

Spiel

et al. 2013

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…As shown in Figure 1, another 24 publications were further excluded. Thus, 14 publications [8][9][10][11][16][17][18][19][20][21][22][23][24][25] (Table 1) covering 17,364 patients were utilized for this report. When a clinical trial reported different outcomes, we then regarded them as a separate study.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Treatment of benign prostatic hyperplasia with finasteride: Evidence from a meta-analysis

Jiang¹,

Zhang²,

Hu³

et al. 2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To clarify the usefulness and safety of finasteride in the treatment of patients with benign prostatic hyperplasia (BPH) compared to placebo group or controls. Methods: In a meta-analysis, PubMed and Web of Science were searched to include relevant studies. The results were combined with a random effect model. Publication bias was evaluated using Egger regression asymmetry test. Results: Fourteen publications involving 17,364 patients were included in the study. Pooled results indicated that International Prostate Symptom Score (IPSS) in the finasteride group was lower [weighted mean difference (WMD) =-0.77, 95% CI=-0.97 to-0.57] compared to the placebo group. The usefulness of finasteride was higher in total prostate volume (TPV) [WMD= 0.13, 95%CI= 0.00 to 0.26] but lower in serum DHT [WMD=-1.18, 95%CI=-1.51 to-0.86] when compared to the placebo group. Drug-related adverse event was higher in the finasteride treatment group when compared to placebo group [summary RR= 1.95, 95%CI= 1.31-2.90]. Conclusion: Finasteride could improve the symptom score (IPSS and TPV) and reduce serum DHT. However, the potential adverse events, especially the drug-related adverse events in Finasteride treatment should be attention.

show abstract

Finasteride for benign prostatic hyperplasia

Tacklind

Fink

MacDonald

et al. 2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia

Cited by 6 publications

References 9 publications

Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results

Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results

Treatment of benign prostatic hyperplasia with finasteride: Evidence from a meta-analysis

Finasteride for benign prostatic hyperplasia

Contact Info

Product

Resources

About